Relative bioavailability of a 5 mg mosapride/10 mg rabeprazole fixed dose combination tablet versus separate single tablets in healthy volunteers: a single-dose randomized open-label crossover study

References

• Furuta T, Shirai N, Sugimoto M, et al. Effect of concomitant dosing of famotidine with lansoprazole on gastric acid secretion in relation to CYP2C19 genotype status. Aliment Pharmacol Ther 2005;22:67-74
   PubMed Web of Science ®Google Scholar
• Londong W, Londong V, Cederberg C, et al. Dose–response study of omeprazole on meal-stimulated gastric acid secretion and gastrin release. Gastroenterology 1983;85:1373-8
   PubMed Web of Science ®Google Scholar
• Hatlebakk JG, Katz PO, Kuo B, et al. Nocturnal gastric acidity and breakthrough on different regimens of omeprazole 40 mg daily. Aliment Pharmacol Ther 1998;12:1235-40
   PubMed Web of Science ®Google Scholar
• Kamiya T, Adachi H, Hirako M, et al. Impaired gastric motility and its relationship to reflux symptoms in patients with nonerosive gastroesophageal reflux disease. J Gastroenterol 2009;44:183-9
   PubMed Web of Science ®Google Scholar
• Achem SR, Robinson M. A prokinetic approach to treatment of gastroesophageal reflux disease. Dig Dis 1998;16:38-46
   PubMed Web of Science ®Google Scholar
• Futagami S, Iwakiri K, Shindo T, et al. The prokinetic effect of mosapride citrate combined with omeprazole therapy improves clinical symptoms and gastric emptying in PPI-resistant NERD patients with delayed gastric emptying. J Gastroenterol 2010;45:413-21
   PubMed Web of Science ®Google Scholar
• Madan K, Ahuja V, Kashyap PC, et al. Comparison of efficacy of pantoprazole alone versus pantoprazole plus mosapride in therapy of gastroesophageal reflux disease: a randomized trial. Dis Esophagus 2004;17:274-8
   PubMed Web of Science ®Google Scholar
• Miyamoto M, Haruma K, Takeuchi K, et al. Frequency scale for symptoms of gastroesophageal reflux disease predicts the need for addition of prokinetics to proton pump inhibitor therapy. J Gastroenterol Hepatol 2008;23:746-51
   PubMed Web of Science ®Google Scholar
• Sachs G, Shin JM, Briving C, et al. The pharmacology of the gastric acid pump: the H+, K+ ATPase. Annu Rev Pharmacol Toxicol 1995;35:277-305
   PubMed Web of Science ®Google Scholar
• Arai K, Takeuchi Y, Watanabe H, et al. Prokinetics influence the pharmacokinetics of rabeprazole. Digestión 2008;78:67-71
   PubMed Web of Science ®Google Scholar
• Anderson T. Pharmacokinetics, metabolism and interactions of acid pump inhibitors. Clin Pharmacokinet 1996;31:9-28
   PubMed Web of Science ®Google Scholar
• World Health Organization. Adherence to long-term therapies. Evidence for Action. Geneva: World Health Organization, 2003. 211 pp
   Google Scholar
• McDonald H, Garg A, Haynes R. Interventions to enhance patient adherence to medication prescriptions. JAMA 2002;288:2868-79
   PubMed Web of Science ®Google Scholar
• Maggiolo F, Ripimonti D, Arici C, et al. Simpler regimens may enhance adherence to antiretrovirals in HIV-infected patients. HIV Clinical Trials 2002;3:371-8
   PubMedGoogle Scholar
• Murray M, Birt J, Manatunga A, et al. Medication compliance in elderly outpatients using twice daily dosing and unit-of-use packaging. Ann Pharmacother 1993;27:616-21
   PubMed Web of Science ®Google Scholar
• Paes A, Bakker A, Soe-Agnie C. Impact of dosage frequency on patient compliance. Diab Care 1997;20:1512-17
   PubMed Web of Science ®Google Scholar
• Wald N, Law M. A strategy to reduce cardiovascular disease by more than 80%. BMJ 2003;326:1423
   PubMedGoogle Scholar
• Administración Nacional de Medicamentos, Alimentos y Tecnología Médica (ANMAT). Available at: http:// www.anmat.gov.ar [Last accessed 10 June 2011]
   Google Scholar
• International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. Tripartite Harmonised Guideline. Clinical Safety Data Management: definitions and standards for expedited reporting E2A Current Step 4 version, dated 27 October 1994. Available at: http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/ Guidelines/Efficacy/E2A/Step4/E2A_Guideline.pdf [Last accessed 10 June 2011]
   Google Scholar
• International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. ICH Harmonised Tripartite Guideline. Guideline for Good Clinical Practice E6(R1). Current Step 4 version, dated 10 June 1996 (including the Post Step 4 corrections). Available at: http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Efficacy/E6_R1/Step4/E6_R1__Guideline.pdf [Last accessed 22 May 2011]
   Google Scholar
• Ritschel WA, Kearns GL. Handbook of Basic Pharmacokinetics – Including Clinical Applications, 6th edn. Washington, DC: American Pharmacists Association, 2004. 432 pp
   Google Scholar
• Conover WJ. Practical Nonparametric Statistics, 2nd edn. New York, NY: Wiley, 1980. 493 pp
   Google Scholar
• Hsuan FC. Estimating treatment means in a mixed-effect ANOVA model for bioequivalence studies. Biometrics. 1993;49:703-13
   PubMed Web of Science ®Google Scholar
• Chow SC, Liu JP. Design and Analysis of Bioavailability and Bioequivalence Studies, 2nd edn. New York, NY: Marcel Dekker, 2000
   Google Scholar
• Schuirmann DJ. A comparison of the two one-sided tests procedure and the power approach for assessing the equivalence of average bioavailability. J Pharmacokinet Biopharm 1987;15:657-80
   PubMedGoogle Scholar
• Anderson S, Hauck WW. A new procedure for testing equivalence in comparative bioavailability and other clinical trials. Comm Statist Theory Methods 1983;12:2663-92
   Web of Science ®Google Scholar
• Marzo A, Balant LP. Bioequivalence. An updated reappraisal addressed to applications of interchangeable multi-source pharmaceutical products. Arzneimittelforschung 1995;45:109-15
   PubMed Web of Science ®Google Scholar
• Shah VP, Midha KK, Dighe S, et al. Analytical methods validation: bioavailability, bioequivalence and pharmacokinetic studies. Conference report. Eur J Drug Metab Pharmacokinet 1991;16:249-55
   PubMed Web of Science ®Google Scholar
• Administración Nacional de Alimentos, Medicamentos y Tecnología Médica. Guidance on good practices for bioavailability/bioequivalence studies conduction [in Spanish]. Available at: http://www.anmat.gov.ar/webanmat/Legislacion/Medicamentos/Disposicion_ANMAT_5040-2006.pdf [Last accessed 22 May 2011]
   Google Scholar
• US Department of Health and Human Services Food and Drug Administration, Center for Drug Evaluation and Research (FDA, CDER). Guidance for Industry: statistical approaches to establishing bioequivalence. Available at: http://fda.gov/ComplianceRegulatoryInformation/Guidances/ucm070244.pdf [Last accessed 22 May 2011]
   Google Scholar
• Sakashita M, Yamaguchi T, Miyazaki H, et al. Pharmacokinetics of the gastrokinetic agent mosapride citrate after single and multiple oral administrations in healthy subjects. Arzneimittelforschung 1993;43:867-72
   PubMed Web of Science ®Google Scholar
• Chen J, Jiang WM, Gao XL, et al. Bioequivalence evaluation of two rabeprazole enteric coated formulations in healthy Chinese volunteers. Eur J Drug Metab Pharmacokinet 2004;29:103-6
   PubMed Web of Science ®Google Scholar
• Mukherjee J, Das A, Chakrabarty US, et al. Bioequivalence study of a fixed dose combination tablet containing rabeprazole and diclofenac sodium in healthy Indian subjects. Arzneimittelforschung 2010;60:506-9
   PubMed Web of Science ®Google Scholar
• Sahoo BK, Das A, Agarwal S, et al. Pharmacokinetics and bioequivalence study of a fixed dose combination of rabeprazole and itopride in healthy Indian volunteers. Arzneimittelforschung 2009;59:451-4
   PubMed Web of Science ®Google Scholar
• Setoyama T, Laurent A, Humphries T, et al. Pharmacokinetics of rabeprazole following single intravenous and oral administration to healthy subjects. Int J Clin Pharmacol Ther 2005;43:37-42
   PubMed Web of Science ®Google Scholar
• Ishizaki T, Horai Y. Review article: cytochrome P450 and the metabolism of proton pump inhibitors – emphasis on rabeprazole. Aliment Pharmacol Ther 1999;13:27-36
   PubMed Web of Science ®Google Scholar
• Kita T, Sakaeda T, Baba T, et al. Different contribution of CYP2C19 in the in vitro metabolism of three proton pump inhibitors. Biol Pharm Bull 2003;26:386-90
   PubMed Web of Science ®Google Scholar
• Horai Y, Kimura M, Furuie H, et al. Pharmacodynamic effects and kinetic disposition of rabeprazole in relation to CYP2C19 genotype. Aliment Pharmacol Ther 2001;15:793-803
   PubMed Web of Science ®Google Scholar
• Fukushima-Uesaka H, Saito Y, Watanabe H. Haplotypes of CYP3A4 and their close linkage with CYP3A5 haplotypes in Japanese population. Hum Mutations 2004;23:100
   PubMedGoogle Scholar